Experience
Otsuka Pharmaceutical Co., Ltd.
Sandoz, Inc.
The U.S. District Court in New Jersey ruled in favor of Finnegan client Otsuka in its patent litigation against several companies seeking FDA approval to market generic copies of Abilify®, the sixth largest selling pharmaceutical in the United States. The court held that the asserted patent claims covering aripiprazole, the active ingredient in Abilify®, are both valid and enforceable. The ruling maintains patent and regulatory protection for Abilify® in the United States until at least April 20, 2015. The court also held that the proposed generics infringe the claims, and accordingly precluded the FDA from approving, and enjoined the respective companies from marketing, the generic products in the United States until at least April 20, 2015.
Otsuka Pharmaceutical Co., Ltd. v. Sandoz, Inc., 3:07-cv-01000, D.N.J., Judges Cooper, Goodman, Hughes
Otsuka Pharmaceutical Co., Ltd. v. Sandoz, Inc., 11-1126, -1127, Fed. Cir., Judges Lourie, Moore, Reyna
The Hillman Group, Inc. v. KeyMe, LLC
The Hillman Group, Inc.
Bright Data Ltd. v. NetNut Ltd.
NetNut Ltd.
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
American Regent, Inc.
Hawk Technology Systems, LLC v. Kirkland's Inc.
Kirkland's Inc.
Rondevoo Technologies, LLC v. RSIP Vision, Inc.
RSIP Vision, Inc.
Eureka Database Solutions, LLC v. Nexidia, Inc.
Nexidia, Inc.
Guntert & Zimmerman Const. Div., Inc. v. GOMACO Corporation
GOMACO Corporation
Koninklijke Philips NV and IP2IPO Innovations, Ltd. v. Boston Scientific Corp.
Koninklijke Philips NV and IP2IPO Innovations, Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.